Table 1.
Patient demographic and clinical characteristics
| Characteristic | Overall, N = 506 | US, n = 257 | Germany, n = 249 |
|---|---|---|---|
| Age (years), mean (SD) | 45.0 (13.8) | 44.8 (14.7) | 45.2 (12.9) |
| Sex | |||
| Male | 184 (36%) | 110 (43%) | 74 (30%) |
| Female | 322 (64%) | 147 (57%) | 175 (70%) |
| Employment status | |||
| Employed part−/full-time | 341 (67%) | 173 (67%) | 168 (67%) |
| Retired | 96 (19%) | 48 (19%) | 48 (19%) |
| Other | 69 (14%) | 36 (14%) | 33 (13%) |
| Disease duration (years)a, mean (SD) | 18.2 (14.9) | 16.5 (15.0) | 20.0 (14.6) |
| Chronic migraine (ever diagnosed) | 239 (47%) | 148 (58%) | 91 (37%) |
| Monthly migraine days, mean (SD) | 8.7 (6.4) | 10.6 (6.8) | 6.7 (5.2) |
| Monthly headache days, mean (SD) | 10.6 (7.1) | 12.2 (7.7) | 8.8 (6.0) |
| Preventive treatment (non-CGRP mAb) | |||
| In the last 3 months | 217 (43%) | 125 (49%) | 92 (37%) |
| In the past | 141 (28%) | 84 (33%) | 57 (23%) |
| Never | 148 (29%) | 48 (19%) | 100 (40%) |
| CGRP mAb treatment | |||
| In the last 3 months | 83 (16%) | 52 (20%) | 31 (12%) |
| In the past | 112 (22%) | 78 (30%) | 34 (14%) |
| Never | 311 (61%) | 127 (49%) | 184 (74%) |
| Satisfied with treatment regimenb | |||
| No | 297 (59%) | 151 (59%) | 146 (59%) |
| Yes | 209 (41%) | 106 (41%) | 103 (41%) |
| Other chronic health condition – any (yes) | 354 (70%) | 197 (77%) | 157 (63%) |
| Physical health condition | 232 (46%) | 137 (53%) | 95 (38%) |
| Mental health condition | 227 (45%) | 130 (51%) | 97 (39%) |
| Anxiety | 159 (31%) | 109 (42%) | 50 (20%) |
| Depression | 148 (29%) | 77 (30%) | 71 (29%) |
| Other | 123 (24%) | 64 (25%) | 59 (24%) |
CGPR Calcitonin gene-related peptide, mAb Monoclonal antibody, SD Standard deviation
aDisease duration was calculated as years since first migraine symptoms, if known, otherwise years since migraine diagnosis (n = 19). Those who did not report years since first symptoms nor years since diagnosis were excluded (n = 20)
bSatisfied with all treatments (acute/preventive/CGRP mAb) taken